RxDoctor Payments Data

Beau Chung, DO

General Practice · Diamond Bar, CANPI 1841746799

Payments from drug & device makers

$480in general payments, 2019–2025

Across 20 payments — averaging $23.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Idorsia Pharmaceuticals US Inc$121
  • Lilly USA, LLC$99
  • AstraZeneca$98
  • Boehringer Ingelheim$67
  • Amgen$40
  • E.r. Squibb & Sons, L.L.C.$22
  • plus $34 from 2 others

What the payments were for

  • Food & beverage$480100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$480 in reported general payments places this provider in the 65th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$43,631
Medicare patients
101
Services billed
555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin24$34,900
OzempicSemaglutide26$23,673
JanumetSitagliptin Phos/Metformin Hcl15$21,371
TrulicityDulaglutide18$21,344
MounjaroTirzepatide15$16,299
EliquisApixaban16$14,718
FarxigaDapagliflozin Propanediol11$11,612
Spiriva RespimatTiotropium Bromide11$8,563
Repatha SureclickEvolocumab12$6,766
EdarbyclorAzilsartan Med/Chlorthalidone13$3,261
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$3,104
Atorvastatin Calcium251$2,501
Icosapent Ethyl12$2,425
Rosuvastatin Calcium153$2,052
Simvastatin183$1,956

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$67$43,46235 claims
Lilly USA, LLCTrulicity, Mounjaro$99$37,64333 claims
Novo NordiskOzempic$18$23,67326 claims
AstraZenecaFarxiga$98$11,61211 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$16$3,26113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 12,963 general practice providers in California.

Other general practice in Diamond Bar

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →